Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
February 11, 2022
The first-ever therapeutic vaccine trial for Merkel cell carcinoma is set to start in April 2022, based in Seattle. This will be a small trial in only eight patients to initially check safety and whether the immune response targeting the Merkel cell polyomavirus is indeed increased in these patients. The trial is only designed for patients whose Merkel cell carcinoma was caused by the Merkel cell polyomavirus.